Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 9/20 | 0.47 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | CA12 | O43570 | 6/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6493993 | 0.92 | TLR7 (0.69) | TLR7CA9CA1CA2CA12 | |
| SCHEMBL6492207 | 0.84 | TLR7 (0.59) | TLR7CA9CA1CA2CA12 | |
| SCHEMBL13837707 | 0.76 | TLR7 (1.00) | TLR7 | |
| SCHEMBL19426705 | 0.73 | CA9 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13219607 | 0.73 | CA1 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13815114 | 0.72 | CA1 (0.71) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13837481 | 0.71 | TLR7 (1.00) | TLR7 | |
| SCHEMBL12185092 | 0.71 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14086339 | 0.70 | CA9 (0.69) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12160082 | 0.69 | CA1 (0.68) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916925-B1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1228147-B1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6630588-B2 | Imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds that have immune response modulating activity and that contain a dye moiety, in particular, a fluorescent dye moiety, e.g., dipyrrometheneboron difluoride dyes | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-29 | — | — | US | disclosed |
| EP-1228147-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M Innovative Properties Company (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6376669-B1 | COMPLEXES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-23 | — | — | US | disclosed |
| WO-2001034709-A1 | DYE LABELED IMIDAZOQUINOLINE COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120141-A1 | Dye labeled imidazoquinoline compounds | LY96, CD74, IFNAR1 | TLR7 41/4885ADRA1D 288/4885ADRA1A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.